Overview
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
Description
This is a prospective, open-label, single-arm clinical study to evaluate the safety, tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).The study plans to explore across three dose levels (1.00 × 10\^6, 3.00 × 10\^6, 9.00 × 10\^6 CAR+ T cells/kg), and 6.00×10\^8 CAR+T cells as maximum dose, aiming to evaluate the safety, tolerability of anti-PD1 armored CD19 CAR-T Cells in r/r DLBCL, explore Maximum Tolerated Dose (MTD) and determine the recommended dose for Phase II. Besides, efficacy, pharmacokinetics and persistence profile of CAR-T cells are also study objectives.
Eligibility
Inclusion Criteria:
- 1\. Subjects voluntarily participate in clinical research and sign informed consent.
- 2\. Adult subjects (age ≥18 ) with relapsed or refractory diffuse large B-cell lymphoma: a) failure to achieve CR after 6 cycles, or PR after 3 cycles, of first-line therapy, or achieve CR after first-line therapy but relapse within 12 months; b) achieve CR after systemic treatment, but are refractory or relapsed, and no plan to transplant, or prepare for transplantation but cannot meet transplantation criteria after second-line therapy; c) not achieve CR after at least two courses of second-line treatment (including autologous stem cell transplantation).
- 3\. Expected survival ≥ 3 months.
- 4\. At least one measurable lesion as per revised IWG response criteria for malignant lymphom (2014 Lugano criteria).
- 5\. CD19 positive expression are detected on tumor cells of subjects by flow cytometry or immunohistochemistry.
- 6\. ECOG score ≤ 2.
- 7\. Subjects with adequate organ functions prior to enrollment, meet the following laboratory values:
- Renal function: serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m².
- Hepatic function: Serum alanine aminotransferase (ALT) ≤ 5 × age-specific ULN and total bilirubin ≤ 2.0 mg/dL, except in subjects with Gilbert-Meulengracht syndrome. If total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN, subjects with Gilbert-Meulengracht syndrome are included.
- Pulmonary reserve: ≤ Grade 1 dyspnea and oxygen saturation \>95% on room air.
- 8\. Stable hemodynamics and left ventricular ejection fraction (LVEF) ≥ 45 % assessed by echocardiography or multi-gated radionuclide angiography (MUGA).
- 9\. Adequate bone-marrow reserve without blood transfusion as defined by:
- Absolute neutrophil count (ANC) ≥ 1 x 10\^9/L.
- Absolute lymphocyte count (ALC) ≥ 0.1 x 10\^9/L.
- Platelets ≥ 50 x 10\^9/L.
- Hemoglobin \>80g/L.
- 10\. In the investigator's judgment, subjects' general condition and all biochemical values are either normal or sufficiently compensated to receive lymphodepletion and CAR-T cell therapy.
Exclusion Criteria:
- 1\. Women who are pregnant or breastfeeding, or planned pregnancy within 6 months.
- 2\. Infectious disease(HIV, Active Tuberculosis ect.).
- 3\. Active infection: hepatitis B, hepatitis C.
- 4\. Abnormal vital signs or refuse to receive examination.
- 5\. Subjects with psychiatric or psychological disorders are unable to complete treatment or efficacy assessment.
- 6.History of severe hypersensitivity or known hypersensitivity to IL-2.
- 7\. Systemic or local severe infection requiring antimicrobial therapy.
- 8\. Significant dysfunction of vital organs (heart, lung, brain, kidney, etc.), or in the investigator's judgment, subjects are unable to be enrolled with any other condition.